In Trials We Trust: US FDA’s Pazdur Urges Diversity To Build Confidence In Medicine

FDA’s top cancer drug regulator is urging industry to increase diversity in trial populations in the name of re-establishing trust in medicine. A webcast to discuss the topic also showcased a bit of industry trust-building in action.